EQUITY RESEARCH - COMPANY REPORT

MEGA LIFESCIENCES

MEGA TB

THAILAND / COMMERCE



TARGET PRICE THB45.00 **CLOSE** THB30.00 **UP/DOWNSIDE** +50.0% **PRIOR TP** THB45.00 **CHANGE IN TP UNCHANGED**

UNCHANGED

TP vs CONSENSUS +2.0%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	15,681	15,426	16,363	17,222
Net profit	1,993	1,957	2,455	2,665
EPS (THB)	2.29	2.24	2.82	3.06
vs Consensus (%)	-	(21.8)	(5.1)	(4.4)
EBITDA	3,285	3,345	3,228	3,520
Recurring net profit	2,327	2,595	2,455	2,665
Core EPS (THB)	2.67	2.98	2.82	3.06
Chg. In EPS est. (%)	-	1.9	-	-
EPS growth (%)	1.6	11.5	(5.4)	8.5
Core P/E (x)	11.2	10.1	10.7	9.8
Dividend yield (%)	5.3	4.1	5.2	5.6
EV/EBITDA (x)	7.2	7.1	7.4	6.8
Price/book (x)	2.8	2.7	2.6	2.5
Net debt/Equity (%)	(26.4)	(25.6)	(23.3)	(20.1)
ROE (%)	29.9	27.4	25.0	26.2



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(13.0)	(21.1)	(29.0)
Relative to country (%)	(5.4)	(8.2)	(21.4)
Mkt cap (USD m)			774
3m avg. daily turnover (USD m)			1.0
Free float (%)			40
Major shareholder	Ur	nistretch Co	Ltd (50%)
12m high/low (THB)		4	3.75/29.75
Issued shares (m)			871.87

Sources: Bloomberg consensus: FSSIA estimates

4Q24E helped by Branded unit

- Expect MEGA to report a core profit of THB619m in 4Q24 (+13.9% q-q, -0.3% y-y), marking its best quarterly profit in 2024.
- The outlook for its Distribution business appears weaker than expected, which may create downside risks to our estimate.
- Maintain our TP at THB45.

Expect 4Q24 core profit to be the highest quarter in 2024

We expect MEGA to report a core profit of THB619m in 4Q24 (+13.9% qq, -0.3% y-y), marking its best quarterly profit in 2024, driven mainly by continued strength across all markets of its Branded business. We anticipate Branded business revenue to grow by +11.6% q-q and +6.7% y-y, with an improved gross margin of 3-4% q-q and y-y. They should help offset significant declines in Distribution business revenue (-25.0% q-q, -29.3% y-y), mainly due to the ongoing economic downturn in Mvanmar.

Profit growth in 2024E, driven by wider margins

Although the profit in 4Q24 should be the highest of the year, it would be lower than our previous estimate due to a worse-than-expected situation in Myanmar. We estimate the full-year 2024 core profit to reach THB2.6b, jumping 11.5% y-y, driven primarily by an overall improvement in the gross margin to 48.7% from 45.3% in 2023, which would help offset stable total revenue.

Situation in distribution business may pose a risk to our estimate

We previously lowered our profit estimates for 2025-26 due to the expectation that Distribution business sales would remain flat compared to 2024. However, since the revenue outlook for the Distribution business in 4Q24 appears weaker than expected, it poses a downside risk to our 2025 revenue projections. Unless the company can drive revenue growth and improve margins in the Branded business to offset the decline, as it did in 2024, we will maintain our current estimates for now.

Maintain our TP at THB45

We maintain our TP at THB45 (DCF, 8.9% WACC, 3.0% LTG), which implies a 2025E P/E of 16x, close to its five-year average and relatively low compared to the sector. We maintain our BUY rating due to the attractive valuation.



Jitra Amornthum Fundamental Investment Analyst on Securities: License no. 014530 jitra.a@fssia.com, +66 2646 9966

Investment thesis

We expect MEGA to report a core profit of THB619m in 4Q24 (+13.9% q-q, -0.3% y-y), marking its best quarterly profit in 2024, driven mainly by continued strength across all markets of its Branded business. It should help offset significant declines in Distribution business revenue (-25.0% q-q, -29.3% y-y), mainly due to the ongoing economic downturn in Myanmar.

Since the revenue outlook for the Distribution business in 4Q24 appears weaker than expected, it poses a downside risk to our 2025 revenue projections. Unless the company can drive revenue growth and improve margins in the Branded business to offset the decline, as it did in 2024, we will maintain our current estimates for now.

Company profile

MEGA is a leading manufacturer and distributor of pharmaceutical, nutraceutical products, and fast-moving consumer goods (FMCG) in developing countries such as Myanmar, Vietnam, and Cambodia. MEGA also develops, manufactures, and sells its nutraceutical products, generic prescription pharmaceutical products, and OTC products under its Mega We Care brand through its distribution network and third-party distributors in 36 countries across the world.


www.megawecare.com

Principal activities (revenue, 2023)

■ Mega We Care - 51.0 %

Maxxcare - 47.2 %

■ OEM - 1.8 %



Source: Mega Lifesciences

Major shareholders

Unistretch Co Ltd - 49.8 %

■ Thai NVDR - 8.0 %

Mr. Vivek Dhawan - 5.3 %

■ Others - 36.9 %



Source: Mega Lifesciences

Catalysts

Key potential catalysts include 1) expedited medicine registrations and listings; 2) widespread medical events such as the Covid-19 pandemic; and 3) the success of new products and markets.

Risks to our call

Downside risks to our DCF-based TP include 1) a delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Event calendar

Date	Event
24 February 2025	4Q24 earnings announcement

Key assumptions

	(unit)	2024E	2025E	2026E
Mega We Care	(THB m)	8,372	8,864	9,573
Growth	(%)	4.6	6.0	8.0
Gross margin	(%)	66.0	65.0	64.9
Maxxcare	(THB m)	6,747	7,185	7,329
Growth	(%)	(8.8)	6.5	2.0
Gross margin	(%)	22.9	23.0	22.8
SG&A to sales (%)	(%)	28.5	28.4	28.1
Maxxcare Growth Gross margin	(THB m) (%) (%)	6,747 (8.8) 22.9	7,185 6.5 23.0	7,3

Source: FSSIA estimates

Earnings sensitivity

- For every 5% change in branded revenue, we project MEGA's 2025 net profit to change by 6%, all else being equal.
- For every 5% change in distribution revenue, we project MEGA's 2025 net profit to change by 1%, all else being equal.
- For every 1% change in overall gross margin, we project MEGA's 2025 net profit to change by 6%, all else being equal.


Source: FSSIA estimates

Exhibit 1: MEGA - 4Q24 earnings preview

Year to Dec 31	4Q23	1Q24	2Q24	3Q24	4Q24E	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	4,158	3,733	3,954	4,001	3,739	(6.6)	(10.1)	15,681	15,426	(1.6)
Cost of sales	(2,252)	(1,984)	(2,038)	(1,866)	(1,785)	(4.3)	(20.7)	(8,586)	(7,911)	(7.9)
Gross profit	1,905	1,749	1,916	2,135	1,953	(8.5)	2.5	5,190	5,469	5.4
Operating costs	(1,104)	(1,066)	(1,140)	(1,099)	(1,094)	(0.5)	(0.9)	(4,191)	(4,549)	8.6
Operating profit	801	682	776	1,035	860	(17.0)	7.3	2,999	3,055	1.8
Operating EBITDA	908	775	872	1,138	947	(16.8)	4.4	3,285	3,345	1.8
Other income	31	22	26	32	9	(70.5)	(70.1)	95	89	(5.9)
Interest expense	(5)	(5)	(9)	(10)	(11)	2.7	131.7	(31)	(36)	13.7
Profit before tax	828	699	793	1,057	858	(18.8)	3.7	2,968	3,019	1.7
Tax	(58)	(71)	(93)	(73)	(238)	226.6	307.0	(269)	(423)	57.1
Reported net profit	473	478	513	383	619	61.9	30.9	1,993	1,957	(1.8)
Extraordinaries										
- Net loss from new businesses	10	9	0	53	54			41	0	
- FX los/(gain)	138	7	(187)	(601)	0			325	(638)	
- Normalising tax expense	0	0	0	0	1			(31)	0	
Core profit	621	494	557	544	619	13.9	(0.3)	2,327	2,595	11.5
Reported EPS (THB)	0.54	0.55	0.59	0.44	0.71	61.9	31.0	2.29	2.24	(1.8)
Core EPS (THB)	0.71	0.57	0.64	0.62	0.71	13.9	(0.3)	2.67	2.98	11.5
Key Ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	45.8	46.8	48.5	53.4	52.3	(1.1)	6.4	45.2	35.5	(9.8)
Operating margin	20.0	18.9	20.3	26.7	23.2	(3.4)	3.2	19.1	19.8	0.7
EBITDA margin	21.8	20.8	22.1	28.5	25.3	(3.1)	3.5	21.0	21.7	0.7
Recurring net margin	14.9	13.2	14.1	13.6	16.6	3.0	1.6	14.8	16.8	2.0
SG&A / Sales	26.6	28.6	28.8	27.5	29.3	1.8	2.7	26.7	29.5	2.8
Revenue breakdown	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Branded business	2,126	1,930	2,140	2,033	2,269	11.6	6.7	8,005	8,372	4.6
Distribution business	1,980	1,737	1,746	1,865	1,399	(25.0)	(29.3)	7,397	6,747	(8.8)
Core revenue after FX effect in Myanmar	1,710	1,483	1,512	1,407	1,512	7.4	(11.6)	6,734	5,914	(12.2)
OEM business	53	65	68	104	71	(31.8)	34.4	280	307	10.0
Gross margin by business unit	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Branded business	64.3	64.3	66.0	65.2	68.2	3.0	3.9	65.0	66.0	1.0
Distribution business	26.6	27.9	27.8	23.7	23.9	0.2	(2.7)	24.5	25.9	1.4
OEM business	25.6	34.9	26.1	41.3	78.0	36.7	52.4	30.2	45.0	14.8


Sources: MEGA, FSSIA estimates

Exhibit 2: Revenue structure



Sources: MEGA, FSSIA estimates

Exhibit 3: Gross margin by business unit



Sources: MEGA, FSSIA estimates

Exhibit 4: Margins





Exhibit 5: Core profit and core profit margin



Sources: MEGA, FSSIA estimates

Sources: MEGA, FSSIA estimates

Exhibit 6: Key changes in assumptions

		Current			Previous			- Change	
	2024E	2025E	2026E	2024E	2025E	2026E	2024E	2025E	2025E
	(THB m)	(THB m)	(%)	(%)	(%)				
Total revenue	15,426	16,363	17,222	15,855	16,363	17,222	(2.7)	0.0	0.0
Mega We Care	8,372	8,864	9,573	8,362	8,864	9,573	0.1	0.0	0.0
Maxxcare	6,747	7,185	7,329	7,185	7,185	7,329	(6.1)	0.0	0.0
OEM	307	314	320	307	314	320	0.0	0.0	0.0
Cost of goods sold	7,911	8,858	9,242	8,501	8,858	9,242	(6.9)	0.0	0.0
Gross profit	7,515	7,505	7,980	7,354	7,505	7,980	2.2	0.0	0.0
SG&A	4,549	4,647	4,838	4,412	4,647	4,838	3.1	0.0	0.0
EBITDA	3,345	3,228	3,520	3,330	3,235	3,527	0.4	(0.2)	(0.2)
Interest expense	36	39	38	36	39	38	0.0	0.0	0.0
Net profit	1,957	2,455	2,665	2,209	2,455	2,665	(11.4)	0.0	0.0
Core profit	2,595	2,455	2,665	2,547	2,455	2,665	1.9	0.0	0.0
Key ratios	(%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(ppt)
Gross margin	48.7	45.9	46.3	46.4	45.9	46.3	2.3	0.0	0.0
Mega We Care	66.0	65.0	64.9	65.1	65.0	64.9	0.9	0.0	0.0
Maxxcare	22.9	23.0	22.8	22.9	23.0	22.8	0.0	0.0	0.0
SG&A to sales	29.5	28.4	28.1	27.8	28.4	28.09	1.7	0.0	0.0
EBITDA margin	21.7	19.7	20.4	21.0	19.8	20.5	0.7	(0.0)	(0.0)
Net margin	12.7	15.0	15.5	13.9	15.0	15.5	(1.2)	0.0	0.0

Source: FSSIA estimates

Exhibit 7: Revenue structures





Exhibit 8: Core profit



Sources: MEGA, FSSIA estimates

Sources: MEGA, FSSIA estimates

Financial Statements

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	15,686	15,681	15,426	16,363	17,222
Cost of goods sold	(8,647)	(8,586)	(7,911)	(8,858)	(9,242)
Gross profit	7,040	7,095	7,515	7,505	7,980
Other operating income	80	95	89	70	69
Operating costs	(4,359)	(4,191)	(4,549)	(4,647)	(4,838)
Operating EBITDA	3,033	3,285	3,345	3,228	3,520
Depreciation	(272)	(286)	(290)	(300)	(309)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,761	2,999	3,055	2,928	3,211
Net financing costs	(29)	(31)	(36)	(39)	(38)
Associates	Ó	Ó	Ô	Ó	Ó
Recurring non-operating income	2	0	(1)	(1)	0
Non-recurring items	(138)	(707)	(638)	Ó	0
Profit before tax	2,596	2,262	2,380	2,889	3,173
Tax	(355)	(269)	(423)	(433)	(508)
Profit after tax	2,242	1,993	1,957	2,455	2,665
Minority interests	_,	-,,,,,,	-,,,,,,	_,	_,000
Preferred dividends	_	_	_	_	_
Other items			_	_	_
Reported net profit	2,242	1,993	1,957	2,455	2,665
Non-recurring items & goodwill (net)	50	335	638	2,433	2,003
Recurring net profit	2,291	2,327	2,595	2,455	2,665
Per share (THB)	2,201	2,027	2,000	2,400	2,000
Recurring EPS *	2.63	2.67	2.98	2.82	3.06
Reported EPS	2.57	2.29	2.24	2.82	3.06
DPS	1.60	1.60	1.23	1.55	1.68
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth	072	012	0,2	0.2	0,2
Revenue (%)	11.0	0.0	(1.6)	6.1	5.3
	23.2	8.3	(1.6)		9.0
Operating EBITDA (%)			1.8	(3.5)	
Operating EBIT (%)	26.2	8.6	1.8	(4.1)	9.7
Recurring EPS (%)	21.4	1.6	11.5	(5.4)	8.5
Reported EPS (%)	15.1	(11.1)	(1.8)	25.4	8.5
Operating performance					
Gross margin inc. depreciation (%)	44.9	45.2	48.7	45.9	46.3
Gross margin exc. depreciation (%)	46.6	47.1	50.6	47.7	48.1
Operating EBITDA margin (%)	19.3	21.0	21.7	19.7	20.4
Operating EBIT margin (%)	17.6	19.1	19.8	17.9	18.6
Net margin (%)	15.2	17.2	16.8	15.0	15.5
Effective tax rate (%)	13.7	11.9	17.8	15.0	16.0
Dividend payout on recurring profit (%)	58.6	51.7	41.5	55.0	55.0
Interest cover (X)	96.2	96.0	86.0	75.5	83.7
Inventory days	172.8	164.6	158.7	145.9	151.0
Debtor days	72.0	80.9	79.7	73.9	75.1
Creditor days	163.5	157.6	137.8	114.1	113.9
Operating ROIC (%)	56.8	58.0	50.7	44.1	44.2
ROIC (%)	37.7	39.8	36.2	32.4	32.8
ROE (%)	28.4	29.9	27.4	25.0	26.2
ROA (%)	17.2	19.0	18.8	17.6	18.4
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Mega We Care	8,053	8,005	8,372	8,864	9,573
Mega We Care Maxxcare	8,053 7,320	8,005 7,397	8,372 6,747	8,864 7,185	9,573 7,329

Sources: Mega Lifesciences; FSSIA estimates

Financial Statements

Mega Lifesciences

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,380	2,699	2,595	2,455	2,665
Depreciation	272	286	290	300	309
Associates & minorities	0	0	0	0	0
Other non-cash items	474	671	(357)	(330)	(370)
Change in working capital	(989)	(1,023)	(759)	(804)	(912)
Cash flow from operations	2,136	2,633	1,769	1,620	1,692
Capex - maintenance	(305)	(294)	(480)	(360)	(440)
Capex - new investment Net acquisitions & disposals	(303)	(294)	(400)	(300)	(440)
Other investments (net)	24	44	173	(2)	0
Cash flow from investing	(281)	(250)	(307)	(362)	(440)
Dividends paid	(1,406)	(1,439)	(1,076)	(1,350)	(1,466)
Equity finance	0	0	0	0	(1,122)
Debt finance	2	(237)	126	4	2
Other financing cash flows	(30)	(32)	(36)	(39)	(38)
Cash flow from financing	(1,433)	(1,708)	(986)	(1,385)	(1,502)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	(165)	(751)	(350)	0	0
Movement in cash	257	(76)	126	(126)	(250)
Free cash flow to firm (FCFF)	1,884.18	2,414.24	1,497.33	1,297.31	1,289.92
Free cash flow to equity (FCFE)	1,662.78	1,362.98	1,202.50	1,224.14	1,215.41
Per share (THB)					
FCFF per share	2.16	2.77	1.72	1.49	1.48
CFE per share	1.91	1.56	1.38	1.40	1.39
Recurring cash flow per share	3.58	4.19	2.90	2.78	2.99
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	4,062	4,309	4,789	5,149	5,589
ess: Accumulated depreciation	(2,161)	(2,334)	(2,624)	(2,924)	(3,233)
Fangible fixed assets (net)	1,901	1,974	2,165	2,225	2,356
ntangible fixed assets (net)	1,329	1,318	1,321	1,403	1,469
ong-term financial assets	0	0	0	0	,
nvest. in associates & subsidiaries	223	221	45	45	45
Cash & equivalents	2,789	2,712	2,839	2,713	2,462
A/C receivable	3,382	3,570	3,170	3,452	3,633
nventories	4,109	3,377	3,251	3,592	3,798
Other current assets	310	330	361	383	403
Current assets	10,590	9,990	9,620	10,139	10,296
Other assets	603	611	630	638	643
Total assets	14,646	14,115	13,782	14,450	14,809
Common equity	8,777	9,302	9,627	10,012	10,361
Minorities etc.	0	0	0	0	(
Total shareholders' equity	8,777	9,302	9,627	10,012	10,361
Long term debt	109	132	146	149	149
Other long-term liabilities	223	244	265	245	248
Long-term liabilities	332	376	412	394	397
A/C payable Short term debt	3,972	3,197	2,558	2,791	2,785
Short term debt Other current liabilities	312 1,254	120 1,119	232 954	234 1,019	236 1,030
Other current habilities	5,538	4,437	3,7 43	1,019 4,044	4,051
Fotal liabilities and shareholders' equity	14,646	14,115	13,782	14,450	14,809
Net working capital	2,575	2,961	3,271	3,616	4,019
nvested capital	6,632	7,086	7,432	7,927	8,532
Includes convertibles and preferred stock which is bei		,	,	,	-,-02
Per share (THB)					
Book value per share	10.07	10.67	11.04	11.48	11.88
зоок value per snare Гangible book value per share	8.54	9.16	9.53	9.87	10.20
Financial strength	0.07	0.10	0.00	0.01	10.20
Net debt/equity (%)	(27.0)	(26.4)	(25.6)	(23.3)	(20.1)
Net debt/total assets (%)	(16.2)	(17.4)	(17.9)	(16.1)	(14.0)
Current ratio (x)	1.9	2.3	2.6	2.5	2.5
CF interest cover (x)	69.5	54.0	48.4	41.8	44.2
/aluation	2022	2023	2024E	2025E	2026E
tecurring P/E (x) * tecurring P/E @ target price (x) *	11.4 16.5	11.2 14.5	10.1 15.1	10.7 16.0	9.8 14.7
Reported P/E (x)	10.5	1 4.5 13.1	13.4	10.7	9.8
Dividend yield (%)	5.3	5.3	4.1	5.2	9.d 5.d
Price/book (x)	3.0	2.8	2.7	2.6	2.5
Price/tangible book (x)	3.5	3.3	3.1	3.0	2.9
EV/EBITDA (x) **	7.8	7.2	7.1	7.4	6.8
EV/EBITDA @ target price (x) **	12.2	11.2	11.0	11.4	10.6
- · · · · ·		3.3	3.2	3.0	2.8
EV/invested capital (x)	3.6	0.0			

Sources: Mega Lifesciences; FSSIA estimates

MEGA LIFESCIENCES PCL (MEGA TB)

Exhibit 9: FSSIA ESG score implication

54.48 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

Exhibit 10: ESG – peer comparison

	FSSIA	Domestic ratings				Global ratings					Bloomberg				
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
COM7	61.78		Υ	Y	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59
MEGA	54.48		Y	Y	4.00	4.00	Declared	Medium	66.56			58.59	24.00	2.39	
BJC	71.33	Υ	Y	Y	4.00	4.00		Medium	55.09	Α		65.19	89.00	2.16	
CRC	64.49		Y	Y	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 11: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.29	_
BESG environmental pillar score	_	1.86	_
BESG social pillar score	_	1.06	_
BESG governance pillar score	_	4.54	_
ESG disclosure score	44.34	53.36	_
Environmental disclosure score	29.84	44.22	_
Social disclosure score	19.44	32.16	_
Governance disclosure score	83.59	83.59	_
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	_	633
GHG scope 2 location-based	_	_	6
GHG Scope 3	_	_	0
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	_	_	914

Sources: Bloomberg; FSSIA's compilation

Exhibit 12: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 202
Fuel used - crude oil/diesel	No	No	N
Waste reduction policy	Yes	Yes	Ye
Hazardous waste	_	_	
Total waste	1	1	
Waste recycled	0	0	-
Waste sent to landfills	_	_	-
Environmental supply chain management	Yes	Yes	N
Water policy	No	Yes	Υe
Water consumption	_	_	
Social			
Human rights policy	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Ye
Quality assurance and recall policy	No	Yes	Ye
Consumer data protection policy	Yes	Yes	Ye
Equal opportunity policy	Yes	Yes	Ye
Gender pay gap breakout	No	No	١
Pct women in workforce	56	56	
Pct disabled in workforce	_	_	
Business ethics policy	Yes	Yes	Y
Anti-bribery ethics policy	Yes	Yes	Y
Health and safety policy	Yes	Yes	1
Lost time incident rate - employees	0	0	
Total recordable incident rate - employees	_	_	
Training policy	Yes	Yes	Y
Fair remuneration policy	No	No	ı
Number of employees – CSR	5,714	6,021	5,7
Employee turnover pct	_	19	-,.
Total hours spent by firm - employee training	70,551	79,892	70,8
Social supply chain management	Yes	Yes	Ye
Governance			
Board size	10	10	
No. of independent directors (ID)	4	4	
No. of women on board	1	1	
No. of non-executive directors on board	8	8	
Company conducts board evaluations	Yes	Yes	Y
No. of board meetings for the year	6	5	
Board meeting attendance pct	100	96	
Board duration (years)	3	3	
Director share ownership guidelines	No	No	1
Age of the youngest director	32	33	:
Age of the oldest director	80	81	
No. of executives / company managers	6	6	
No. of female executives	1	1	
Executive share ownership guidelines	No	No	1
Size of audit committee	3	3	
No. of ID on audit committee	3	3	
Audit committee meetings	4	4	
Audit meeting attendance %	100	100	1
Size of compensation committee	3	3	
No. of ID on compensation committee	1	1	
·	•	2	
No. of compensation committee meetings	2		4
Compensation meeting attendance %	100	100	1
Size of nomination committee	3	3	
	2	2	
No. of nomination committee meetings		400	
No. of nomination committee meetings Nomination meeting attendance % Sustainability governance	100	100	1

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the anr Only the top inclusion.	sed on the com nual S&P Glob -ranked comp	transparent, rules-based on panies' Total Sustainabilit pal Corporate Sustainabilit anies within each industry	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.						
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing b Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the lar trading of th shareholders some key disque ependent direct related to CG,	onsibility in Environmental ransparency in Governance preemptive criteria, with the board members and es, and combined holding moualifying criteria include: 1 ctors and free float violation, social & environmental in parnings in red for > 3 year	te, updated annually. two crucial conditions: two crucial crucial crucial conditions: two crucial cruc	To be eligible for <u>SETESG inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETESG Index</u> is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.					
CG Score by Thai nstitute of Directors Association (Thai IOD)	annually by Thailand (SI	the Thai IOD,	th in sustainable developm with support from the Stoc ts are from the perspective s.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).						
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiabilit	re incorporated and sufficiently are CG componer AGM proced and after the resufficient informate second assessy; and 3) openne	which shareholders' rights d into business operations y disclosed. All form impor lents to be evaluated annutures before the meeting (ameeting (10%). (The first as attion for voting; and 2) facilitating the ease of attending means for Q&A. The third involves less, resolutions and voting resu	and information is rtant elements of two ually. The assessment 45%), at the meeting issesses 1) advance on how voting rights can be eetings; 2) transparency the meeting minutes that	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.					
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	ent of key contr e Certification in leciding to becon f Intent to kick off including risk ass	Checklist include corruption rols, and the monitoring an is good for three years. The act of an 18-month deadline to submessment, in place of policy and tablishment of whistleblowing cull stakeholders.)	and developing of art by submitting a mit the CAC Checklist for d control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on ar risk is unma	n assessment of naged. Sources	isk rating provides an over of how much of a compan s to be reviewed include corpo	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored.						
	information, co		her media, NGO reports/websi k, ESG controversies, issuer fe riews		NEGL	Low	Medium	High	Severe	
	reports, and q	daily & peer rev	iews.		0-10	10-20	20-30	30-40	40+	
ESG Book	positioned to the principle helps explai over-weighti	o outperform o of financial m n future risk-ad	sustainable companies that pover the long term. The me atteriality including informa djusted performance. Mate ith higher materiality and re erly basis.	ethodology considers ation that significantly eriality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.					
<u>MSCI</u>			measure a company's ma nd laggards according to t						nethodology to	
	AAA	8.571-10.00	0		· · · · · · · · · · · · · · · · · · ·					
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most si	yınıncarın ESG fis	къ ани орропипіте	5 5		
	Α	5.714-7.142	2							
	BBB	4.286-5.713	3 Average:	a mixed or unexception industry peers	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers					
	ВВ	2.857-4.285	5							
	В	1.429-2.856	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks						
	CCC	0.000-1.428	8							
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.									
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. (Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)									
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.									
Bloomberg	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.									
	ESG Disclos	•	Disclosure of a company			•	-			

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION


Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 30.00	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 06-Feb-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.